#Enzian分类与修订版美国生殖医学学会分期对深部子宫内膜异位症女性疾病范围描述的比较
这项前瞻性多中心研究纳入735例因深部子宫内膜异位症接受根治性手术的女性,术中同时用#Enzian分类和rASRM分期描述疾病范围。结果显示rASRM分期1和2中已存在深部子宫内膜异位病灶,使用rASRM分期会低估疾病严重程度。
要点
- rASRM分期1的31例中,65%(20例)在#Enzian B区(宫骶韧带/宫旁)有深部子宫内膜异位症。
- rASRM分期1的31例中,45%(14例)在#Enzian A区(阴道/直肠阴道隔)有深部子宫内膜异位症。
- rASRM分期1的31例中,26%(8例)在#Enzian C区(直肠)有深部子宫内膜异位症。
核心结论
- 深部子宫内膜异位病灶的患病率和严重程度以及受累#Enzian区域总数随rASRM分期升高而平均增加,但rASRM分期1和2中也存在深部子宫内膜异位病灶,使用rASRM分类会低估疾病严重程度。
研究设计与样本
- 前瞻性多中心研究,2020年1月至2021年5月纳入735例因深部子宫内膜异位症在子宫内膜异位症三级转诊中心接受根治性手术的女性。
- 术中同时使用#Enzian分类和rASRM分类描述疾病范围。
主要发现
- rASRM分期1的31例中,65%(20例)在#Enzian B区(宫骶韧带/宫旁)有深部子宫内膜异位症,45%(14例)在#Enzian A区(阴道/直肠阴道隔)有深部子宫内膜异位症,26%(8例)在#Enzian C区(直肠)有深部子宫内膜异位症。
- 从rASRM分期1至4,深部子宫内膜异位病灶(#Enzian A、B、C、FB(膀胱)、FU(输尿管)、FI(其他肠道部位)、FO(其他生殖道外部位)区)的患病率和严重程度平均逐渐增加。
- 从rASRM分期1至4,#Enzian P区(腹膜)、O区(卵巢)和T区(输卵管卵巢单元)的子宫内膜异位病灶和粘连的患病率和严重程度平均逐渐增加。
- 从rASRM分期1至4,受深部子宫内膜异位病灶累及的#Enzian区域总数平均逐渐增加,rASRM分期4患者中最多有6个受累区域。
临床怎么用
- #Enzian分类除评估卵巢和输卵管的子宫内膜异位病灶及粘连外,还包括深部子宫内膜异位症的评估,可能对深部子宫内膜异位症女性的疾病定位和范围提供全面描述。
局限性
- 观察者间变异性可能是本研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How is endometriosis extent described by the #Enzian classification compared to the revised American Society for Reproductive Medicine (rASRM) stages in women undergoing radical surgery for deep endometriosis (DE)? SUMMARY ANSWER: The prevalence and severity grade of endometriotic lesions and adhesions as well as the total number of #Enzian compartments affected by DE increase on average with increasing rASRM stage; however, DE lesions are also present in rASRM stages 1 and 2, leading to an underestimation of disease severity when using the rASRM classification. WHAT IS KNOWN ALREADY: Endometriotic lesions can be accurately described regarding their localization and severity by sonography as well as during surgery using the recently updated #Enzian classification for endometriosis. STUDY DESIGN, SIZE, DURATION: This was a prospective multicenter study including a total of 735 women between January 2020 and May 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Disease extent in women undergoing radical surgery for DE at tertiary referral centers for endometriosis was intraoperatively described using the #Enzian and the rASRM classification. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 735 women were included in the study. Out of 31 women with rASRM stage 1, which is defined as only minimal disease, 65% (i.e. 20 women) exhibited DE in #Enzian compartment B (uterosacral ligaments/parametria), 45% (14 women) exhibited DE in #Enzian compartment A (vagina/rectovaginal septum) and 26% (8 women) exhibited DE in #Enzian compartment C (rectum). On average, there was a progressive increase from rASRM stages 1-4 in the prevalence and severity grade of DE lesions (i.e. lesions in #Enzian compartments A, B, C, FB (urinary bladder), FU (ureters), FI (other intestinal locations), FO (other extragenital locations)), as well as of endometriotic lesions and adhesions in #Enzian compartments P (peritoneum), O (ovaries) and T (tubo-ovarian unit). In addition, the total number of #Enzian compartments affected by DE lesions on average progressively increased from rASRM stages 1-4, with a maximum of six affected compartments in rASRM stage 4 patients. LIMITATIONS, REASONS FOR CAUTION: Interobserver variability may represent a possible limitation of this study. WIDER IMPLICATIONS OF THE FINDINGS: The #Enzian classification includes the evaluation of DE in addition to the assessment of endometriotic lesions and adhesions of the ovaries and tubes and may therefore provide a comprehensive description of disease localization and extent in women with DE. STUDY FUNDING/COMPETING INTEREST(S): No funding was received for this study. All authors declare that they have no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Montanari E, Bokor A, Szabó G, et al. Comparison of #Enzian classification and revised American Society for Reproductive Medicine stages for the description of disease extent in women with deep endometriosis. Hum Reprod. 2022. PMID: 36066464. doi:10.1093/humrep/deac187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。